Immune checkpoint blocking therapies do not always work and come with some risks, but identifying non-responders and patients at risk of adverse events is becoming easier and more accurate.
References
Quesada, J. R. et al. N. Engl. J. Med. 310, 15–18 (1984).
Zitvogel, L. et al. Nat. Rev. Immunol. 15, 405–414 (2015).
Boukhaled, G. M. et al. Nat. Immunol. https://doi.org/10.1038/s41590-022-01262-7 (2022).
Zhang, T. et al. MedComm 2, 618–653 (2021).
Boukhaled, G. M., Harding, S. & Brooks, D. G. Annu. Rev. Pathol. 16, 167–198 (2021).
Benci, J. L. et al. Cell 167, 1540–1554.e12 (2016).
Liu, J. et al. Nat. Can. 2, 457–473 (2021).
Bai, X. et al. Clin. Cancer Res. 27, 5993–6000 (2021).
Nishino, M. et al. Nat. Rev. Clin. Oncol. 14, 655–668 (2017).
Litchfield, K. et al. Cell 184, 596–614.e14 (2021).
Zhang, J. et al. Trends Immunol. 55, 738–748 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Su, S., Song, E. The systemic effect of type 1 interferon responsiveness on tumor immunotherapy. Nat Immunol 23, 1141–1143 (2022). https://doi.org/10.1038/s41590-022-01275-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41590-022-01275-2
- Springer Nature America, Inc.